Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183624 | 1.00 | DRD2 (0.35) | DRD2DRD3MEN1KMT2AMAPT | |
| SCHEMBL6184376 | 0.91 | KDM4E (0.33) | DRD2DRD3MEN1KMT2AMAPT | |
| SCHEMBL6184374 | 0.91 | KDM4E (0.33) | DRD2DRD3MEN1KMT2AMAPT | |
| SCHEMBL6181610 | 0.89 | KCNH2 (0.33) | DRD2DRD3MEN1KMT2AKDM4E | |
| SCHEMBL6181606 | 0.89 | KCNH2 (0.33) | DRD2DRD3MEN1KMT2AKDM4E | |
| SCHEMBL4510781 | 0.82 | DRD2 (0.43) | DRD2DRD3 | |
| SCHEMBL6183285 | 0.79 | LMNA (0.36) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL6183281 | 0.79 | LMNA (0.36) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL6184183 | 0.79 | ALDH1A1 (0.35) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL4501494 | 0.77 | ACACB (0.41) | DRD2DRD3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143407-A1 | Process for porducing quinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2005-06-30 | — | — | US | disclosed |
| EP-1518856-A1 | PROCESS FOR PRODUCING QUINOLONECARBOXYLIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143407-A1 | Process for porducing quinolonecarboxylic acid derivative | PORCN, POR, COASY | DRD2 2152/4885DRD3 2675/4885MEN1 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.